Four PD-L1 IHC (22C3, 28-8, SP142, SP263) tests, which help identify patients who may benefit from immunotherapies; PD-L1 IHC testing has become a crucial tool for personalizing treatment ...

Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

Nivolumab and atezolizumab are approved without PD-L1 testing, though US Food and Drug Administration-cleared complementary PD-L1 tests are available for both. PD-L1 IHC assays used to assess PD-L1 ...

Immunohistochemistry (IHC) is a special test used by pathologists to detect specific molecules on cells. It is widely used in clinical oncology for categorizing solid cancer tumors and blood ...

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE ...

Tempus AI, Inc. TEM recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to ...

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients Provided by PR Newswire May 12, 2025, 3:30:00 AM ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests.

After analyzing the data of both tests, it was clear that NGS identified more patients with microsatellite instability. However, in their practices, oncologists use IHC much more often.

Companion diagnostic immunohistochemistry (IHC) tests do not yet incorporate the tools and principles of laboratory metrology. Basic analytic assay parameters, such as lower limit of detection ...

At a special September commission session, Swinford said the lab had processed over 11,000 antemortem IHC tests over the summer in the wake of the emergency rules.